Abbonarsi

Executive summary: Consensus treatment guidelines for the use of methotrexate for inflammatory skin disease in pediatric patients - 14/05/24

Doi : 10.1016/j.jaad.2023.12.074 
Heather A. Brandling-Bennett, MD a, b, , Lisa M. Arkin, MD c, Yvonne E. Chiu, MD d, Adelaide A. Hebert, MD e, Jeffrey P. Callen, MD f, Leslie Castelo-Soccio, MD g, Dominic O. Co, MD c, Kelly M. Cordoro, MD h, Megan L. Curran, MD i, Austin M. Dalrymple, MD j, k, Carsten Flohr, MD l, Ken B. Gordon, MD d, Diane Hanna, DNP m, Alan D. Irvine, MD n, Susan Kim, MD h, A. Yasmine Kirkorian, MD o, p, Irene Lara-Corrales, MD q, Jill Lindstrom, MD r, Amy S. Paller, MD s, Melissa Reyes, MD t, Wendy Smith Begolka, MBS u, Wynnis L. Tom, MD v, w, Abby S. Van Voorhees, MD x, Ruth Ann Vleugels, MD y, z, Lara Wine Lee, MD aa, Olivia Davies, MD d, Elaine C. Siegfried, MD j, k
a Seattle Children's Hospital, Seattle, Washington 
b Division of Dermatology, Department of Pediatrics, University of Washington, Seattle, Washington 
c Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 
d Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin 
e Department of Dermatology, UTHealth McGovern Medical School at Houston, Houston, Texas 
f Department of Dermatology, University of Louisville School of Medicine, Louisville, Kentucky 
g Dermatology Branch, National Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 
h Department of Dermatology, University of California, San Francisco, San Francisco, California 
i Division of Rheumatology, Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, Colorado 
j Division of Rheumatology, Department of Pediatrics, Saint Louis University School of Medicine, St. Louis, Missouri 
k SSM Health Cardinal Glennon Children's Hospital, St. Louis, Missouri 
l Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust, London, UK 
m Modern Dermatology, Shawnee, Kansas 
n Department of Paediatric Dermatology, Trinity College Dublin, Dublin, Ireland 
o Department of Dermatology, George Washington University School of Medicine & Health Sciences, Washington, District of Columbia 
p Children's National Hospital, Washington, District of Columbia 
q Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada 
r Walter Reed National Military Medical Center, Bethesda, Maryland 
s Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 
t Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, Maryland 
u National Eczema Association, Novato, California 
v Departments of Dermatology and Pediatrics, University of California, San Diego School of Medicine, San Diego, California 
w Rady Children's Hospital-San Diego, San Diego, California 
x Department of Dermatology, Eastern Virginia Medical School, Norfolk, Virginia 
y Brigham and Women's Hospital, Boston, Massachusetts 
z Department of Dermatology, Harvard Medical School, Boston, Massachusetts 
aa Department of Dermatology, Medical University of South Carolina, Charleston, South Carolina 

Correspondence to: Heather A. Brandling-Bennett, MD, Seattle Children's Hospital, 4800 Sand Point Way NE, M/S OC.9.835, Seattle, WA 98105Seattle Children's Hospital4800 Sand Point Way NEM/S OC.9.835SeattleWA98105

Key words : adolescent, child, consensus, guidelines, methotrexate, pediatric



 Funding sources: This work was supported by a generous grant from the Pediatric Dermatology Research Alliance (PeDRA), with additional funding from the National Eczema Association (NEA) and the National Psoriasis Foundation (NPF). Funding sources had no influence on the content of the guidelines beyond several authors being members of the funding sources and review and approval of the final document by the Pediatric Dermatology Research Alliance (PeDRA) Best Practices Task Force.
 Disclaimer: This publication has been reviewed by FDA and determined not to be consistent with the Agency's views or policies. It reflects only the views and opinions of the authors.
 Patient consent: Not applicable.
 IRB approval status: Not applicable.


© 2024  American Academy of Dermatology, Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 90 - N° 6

P. 1271-1275 - giugno 2024 Ritorno al numero
Articolo precedente Articolo precedente
  • Associations between dermatologic immune-related adverse event morphologies and systemic immunomodulatory/immunosuppressive treatment: A large retrospective cohort study
  • Rachel M. Reardon, Katherine L. Perlman, Maria S. Asdourian, Nishi Shah, Ted V. Jacoby, Leah L. Thompson, Kerry L. Reynolds, Yevgeniy R. Semenov, Steven T. Chen
| Articolo seguente Articolo seguente
  • Combined reflectance confocal microscopy and optical coherence tomography in the evaluation of cutaneous squamous cell carcinoma
  • Abdullah Aleisa, Miguel Cordova, Catherine Payulert, Haifa Aldawood, Erica H. Lee, Kishwer S. Nehal, Anthony M. Rossi

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.